104 results
Page 2 of 6
8-K
EX-2.1
xjwya f3226wsii
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFA14A
h5hi6
16 Dec 22
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
g3lt98p
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
PRRN14A
tnscrni4
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
DEFA14A
EX-99.1
xnp fhzh62
5 Dec 22
Additional proxy soliciting materials
9:59pm
8-K
EX-99.1
ek3i04z
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
PRRN14A
zpgbqilc7mywd51zuoxu
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PREC14A
atl20wcpw 1zyve
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
8-K
EX-99.1
h1je52
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
5j6qquagw jv
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
ksty2 agu
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
1k3z2grkuoe
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
rqyh5mmx l3vs
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
cb6 92bg83gdxut
27 Jul 22
Other Events
7:30am
424B5
1mp5 vu2vn
22 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-10.1
9c8b69f58
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-99.1
qb3gcvkmj4c
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-99.1
volqx nx67becum5
23 May 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5:42pm